CDK1 and cancer: By the m6A-dependent manner or the m6A-independent manner, VIRMA has been shown to promote cancer cell proliferation, apoptosis resistance, invasion, migration, and tumor progression through different pathways, including the TGF-β signaling pathway by targeting ID2, cell cycle pathway by targeting CDK1, CCAT1/2 pathway by upregulating its lncRNA stability, GATA3 pathway by upregulating pre-GATA3 mRNA degradation, and TNF pathway by targeting c-Jun [20, 29–32, 42–44].